Species |
Human |
Protein Construction |
BNP (Ser103-His134) Accession # P16860 |
|
Purity |
> 97% as analyzed by SDS-PAGE > 97% as analyzed by HPLC |
Endotoxin Level |
< 1 EU/μg of protein by LAL method |
Expression System |
E. coli |
Theoretical Molecular Weight |
3.5 kDa |
Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
Target Background |
Natriuretic Peptide Precursor B acts as a cardiac hormone with a variety of biological actions including natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. It is thought to play a key role in cardiovascular homeostasis. Helps restore the body's salt and water balance. Improves heart function. |
Synonyms |
Brain natriuretic peptide; Brain natriuretic peptide 32; BNP(1-32); BNP-32 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.